A high-level task force has been set up to work on frontiers of science related to vaccines and drug testing to fight coronavirus, the Union health ministry said on Sunday.
Addressing a media briefing here, Lav Agarwal, Joint Secretary, health ministry, said NITI Aayog member and principal scientific advisor to the government will be co-chair of the task force.
"Besides AYUSH, the Indian Council of Medical Research (ICMR), Department of Science and Technology, Biotechnology, Council of Scientific and Industrial Research (CSIR), Defence Research and Development Organisation (DRDO), DG Health Services and Drug Controller will also be the members of the task force, he said.
The senior official asserted that the task force aims to enable and speed up the industry and international efforts being made to fight COVID-19.
"The objective of this task force is academia, and to enable and speed up industry and international efforts for COVID-19, he said.
"The Department of Biotechnology has been made a central coordination agency to identify pathways for vaccine development. We will make a dynamic list of national and international efforts for vaccine development and monitor the progress and provide required facilitation at government level," Agarwal said.
The ministry also said that the task force will work on clinical cohorts, which will be focusing on long-term follow up of people for having better understanding of the disease and its management.
"We will also collect bio-specimens for further vaccine and drug trials. This will be separate from sample testing work," Agarwal added.
The health ministry said 1,334 fresh COVID-19 cases were reported since Saturday with 27 deaths in the last 24 hours.
The total COVID-19 cases in the country stand at 15,712 and deaths at 507. As many as 2,231 COVID-19 patients, which is around 14.19 per cent, have been cured, Agarwal said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
